Neurogene, Inc. Common Stock

NGNENASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
33.69 USD
↘ 1.52 (4.32%)AT CLOSE (11:59 AM EDT)
33.67
↘ 0.02 (0.06%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
33.67
↘ 0.02 (0.06%)
🔴Market: CLOSED

Neurogene, Inc. Common Stock (NGNE) is currently trading at $33.57. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, NGNE trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Sep 15, 2026.

Open?$35.04
High?$35.04
Low?$33.46
Prev. Close?$35.21
Volume?147.6K
Avg. Volume?207.1K
VWAP?$33.92
Rel. Volume?0.71x
Bid / Ask
Bid?$30.95 × 100
Ask?$40.10 × 200
Spread?$9.15
Midpoint?$35.53
Valuation & Ratios
Market Cap?704.6M
Shares Out?20.0M
Float?12.9M
Float %?64.3%
P/E Ratio?N/A
P/B Ratio?3.25
EPS?-$5.55
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
131
Market Cap
704.6M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.neurogene.com
Listed
2023-12-19
Address
535 W 24TH STREET
NEW YORK, NY 10011
Phone: (877) 237-5020
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
23
Short Sent.?
39
Piotroski F-Score?0/9Weak
Altman Z-Score?12.51Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?24.36%Squeeze Risk
Short Interest?3.1M
Days to Cover?13.6
Free Float12.9M
Avg Daily Volume230.8K
Settlement Date2026-08-31
Financial Health
Current Ratio?10.64Strong
Quick Ratio?10.64Strong
Cash Ratio?5.23Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
52
3.25FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-5.0CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-51.2%WEAK▾
ROA?
S&P
3
-45.5%WEAK▾
Cash Flow & Enterprise
FCF?$-87707000
Enterprise Value?$592.1M
Fundamentals ratios updated end of day
MarketsMoversWatchlist